Hatch quizzes FDA on andro
This article was originally published in The Tan Sheet
"It appears that FDA is not taking action against [androstenedione] products because you can't decide whether it's a supplement or a drug," Sen. Orrin Hatch (R-Utah) tells FDA General Counsel Daniel Troy during an Aug. 1 Senate Judiciary committee hearing on the "Greater Access to Affordable Pharmaceuticals Act." "I'm counting on FDA moving forward on this, to protect the public health," Hatch continued, "because I think this inaction has been going on far too long." Troy promised to relay concerns to FDA Commissioner Mark McClellan, MD/PhD...
You may also be interested in...
Androstenedione would be regulated as a controlled substance under legislation offered by Sen. Joseph Biden (D-Del.), and co-sponsored by Sens. Orrin Hatch (R-Utah), Tom Harkin (D-Iowa) and Charles Grassley (R-Iowa)
Teva will not engage in paragraph IV patent-infringement litigation with Evoke Pharma over the originator’s Gimoti (metoclopramide) nasal spray treatment for diabetic gastroparesis, following a court order.
Amgen’s biosimilars sales are on the decline, largely due to erosion of its oncology portfolio. However, the debut of first US Humira rival Amjevita, along with planned versions of Stelara and Eylea, are expected to push the segment back into growth.